[go: up one dir, main page]

MX2018014787A - Ratones que producen proteinas de union que comprenden dominios vl. - Google Patents

Ratones que producen proteinas de union que comprenden dominios vl.

Info

Publication number
MX2018014787A
MX2018014787A MX2018014787A MX2018014787A MX2018014787A MX 2018014787 A MX2018014787 A MX 2018014787A MX 2018014787 A MX2018014787 A MX 2018014787A MX 2018014787 A MX2018014787 A MX 2018014787A MX 2018014787 A MX2018014787 A MX 2018014787A
Authority
MX
Mexico
Prior art keywords
mice
binding proteins
light chain
variable domain
gene segments
Prior art date
Application number
MX2018014787A
Other languages
English (en)
Inventor
Andrew J Murphy
Lynn Macdonald
Cagan Gurer
Sean Stevens
Karolina A Hosiawa
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44543797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018014787(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2018014787A publication Critical patent/MX2018014787A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Environmental Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a ratones genéticamente modificados y a métodos de producción utilizándolos, en donde el ratón comprende un reemplazo de la totalidad o sustancialmente la totalidad de segmentos de genes de la región V de cadena ligera, segmentos de genes de la región D, y segmentos de genes de la región J, con al menos un segmento de gen de la región V de cadena ligera y al menos un segmento de gen de la región J de cadena ligera. Se proporcionan ratones que producen proteínas de unión que comprenden un dominio variable de cadena ligera ligado de manera operable a una región constante de cadena pesada. Se proporcionan proteínas de unión que contienen un dominio variable de cadena ligera de inmunoglobulina, incluyendo un dominio variable de cadena ligera somáticamente hipermutado, fusionado con una región constante de cadena pesada. Se proporcionan células, embriones y ratones modificados que codifican secuencias para la producción de proteínas de unión.
MX2018014787A 2010-08-02 2011-08-02 Ratones que producen proteinas de union que comprenden dominios vl. MX2018014787A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36990910P 2010-08-02 2010-08-02
PCT/US2011/046196 WO2012018764A1 (en) 2010-08-02 2011-08-02 Mice that make binding proteins comprising vl domains

Publications (1)

Publication Number Publication Date
MX2018014787A true MX2018014787A (es) 2023-02-14

Family

ID=44543797

Family Applications (5)

Application Number Title Priority Date Filing Date
MX2016014021A MX350591B (es) 2010-08-02 2011-08-02 Ratones que producen proteinas de union que comprenden dominios vl.
MX2013001360A MX345251B (es) 2010-08-02 2011-08-02 Ratones que producen proteinas de union que comprenden dominios vl.
MX2018014787A MX2018014787A (es) 2010-08-02 2011-08-02 Ratones que producen proteinas de union que comprenden dominios vl.
MX2017006698A MX363084B (es) 2010-08-02 2011-08-02 Ratones que producen proteinas de union que comprenden dominios vl.
MX2023001793A MX2023001793A (es) 2010-08-02 2013-02-01 Ratones que producen proteinas de union que comprenden dominios vl.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2016014021A MX350591B (es) 2010-08-02 2011-08-02 Ratones que producen proteinas de union que comprenden dominios vl.
MX2013001360A MX345251B (es) 2010-08-02 2011-08-02 Ratones que producen proteinas de union que comprenden dominios vl.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2017006698A MX363084B (es) 2010-08-02 2011-08-02 Ratones que producen proteinas de union que comprenden dominios vl.
MX2023001793A MX2023001793A (es) 2010-08-02 2013-02-01 Ratones que producen proteinas de union que comprenden dominios vl.

Country Status (27)

Country Link
US (7) US9516868B2 (es)
EP (3) EP2947151A1 (es)
JP (6) JP6146913B2 (es)
KR (4) KR102306967B1 (es)
CN (4) CN105753979B (es)
AU (1) AU2011285919C1 (es)
BR (1) BR112013002695B1 (es)
CA (2) CA2807282A1 (es)
CY (1) CY1118562T1 (es)
DK (1) DK2601298T3 (es)
ES (1) ES2612459T3 (es)
HK (1) HK1217511A1 (es)
HR (1) HRP20170322T1 (es)
HU (1) HUE031903T2 (es)
IL (4) IL271804B2 (es)
LT (1) LT2601298T (es)
MX (5) MX350591B (es)
MY (1) MY172618A (es)
NZ (2) NZ707327A (es)
PL (1) PL2601298T3 (es)
PT (1) PT2601298T (es)
RS (1) RS55495B1 (es)
RU (2) RU2612903C2 (es)
SG (3) SG187673A1 (es)
SI (1) SI2601298T1 (es)
SM (2) SMT201700023T1 (es)
WO (1) WO2012018764A1 (es)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2288623B1 (en) * 2008-05-23 2013-07-10 Ablexis, LLC Method of generating single vl domain antibodies in transgenic animals
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
AU2010269978B2 (en) 2009-07-08 2016-11-03 Kymab Limited Animal models and therapeutic molecules
PL2501817T5 (pl) 2010-02-08 2021-08-16 Regeneron Pharmaceuticals, Inc. Mysz o wspólnym łańcuchu lekkim
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
CN103025884B (zh) 2010-07-26 2015-11-25 特里安尼公司 转基因动物和使用方法
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
CN105753979B (zh) 2010-08-02 2021-05-07 瑞泽恩制药公司 制造包含vl结构域的结合蛋白的小鼠
SMT202100357T1 (it) 2011-08-05 2021-07-12 Regeneron Pharma Topi di catena leggera universale umanizzata
EP3741862A1 (en) 2011-09-19 2020-11-25 Kymab Limited Animals, repertoires & methods for the production of human antibodies
DK3311661T3 (da) * 2011-09-19 2022-07-11 Kymab Ltd Manipulation af immunoglobulin-gendiversitet og terapeutiske lægemidler med flere antistoffer
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
KR20140082824A (ko) 2011-10-17 2014-07-02 리제너론 파아마슈티컬스, 인크. 제한된 면역글로불린 중쇄 마우스
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
HUE044266T2 (hu) 2011-12-20 2019-10-28 Regeneron Pharma Humanizált könnyûláncú egerek
SI2809150T1 (sl) * 2012-02-01 2019-11-29 Regeneron Pharma Humanizirane miši, ki izražajo težke verige z domenami VL
US9914929B2 (en) 2012-03-14 2018-03-13 Innovative Targeting Solutions Inc. Generating targeted sequence diversity in fusion proteins
WO2013134880A1 (en) 2012-03-14 2013-09-19 Innovative Targeting Solutions Inc. Generating targeted sequence diversity in proteins
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
RU2656155C2 (ru) 2012-06-12 2018-05-31 Регенерон Фармасьютикалз, Инк. Гуманизированные не относящиеся к человеку животные с ограниченными локусами тяжелой цепи иммуноглобулина
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
KR101764800B1 (ko) 2013-02-20 2017-08-04 리제너론 파마슈티칼스 인코포레이티드 변형된 면역글로불린 중쇄 서열을 갖는 비인간 동물
JP6529957B2 (ja) * 2013-03-13 2019-06-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 限られた免疫グロブリン軽鎖レパートリーを発現するマウス
ES2996807T3 (en) 2013-03-15 2025-02-13 Regeneron Pharma Biologically active molecules, conjugates thereof, and therapeutic uses
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
WO2015031396A1 (en) 2013-08-26 2015-03-05 Regeneron Pharmaceuticals, Inc. Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
SG11201602236SA (en) 2013-10-01 2016-04-28 Kymab Ltd Animal models and therapeutic molecules
FR3011249A1 (es) * 2013-10-01 2015-04-03 Kymab Ltd
SG11201607015VA (en) 2014-03-21 2016-09-29 Regeneron Pharma V<sb>L</sb> ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICS
CA3124228C (en) * 2014-03-21 2024-05-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
JP2018508224A (ja) * 2015-03-19 2018-03-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗原を結合する軽鎖可変領域を選択する非ヒト動物
BR112017020149A8 (pt) 2015-03-27 2023-05-02 Regeneron Pharma Derivados de maitansinoide, conjugados dos mesmos e métodos de uso
CA2986942C (en) 2015-06-05 2025-07-22 Ac Immune Sa Anti-tau antibodies and their methods of use
EP3384030A4 (en) 2015-12-03 2019-07-03 Trianni, Inc. IMPROVED IMMUNOGLULINIVITY
WO2017132173A1 (en) 2016-01-25 2017-08-03 Regeneron Pharmaceuticals, Inc. Maytansinoid derivatives, conjugates thereof, and methods of use
US11053288B2 (en) 2016-02-04 2021-07-06 Trianni, Inc. Enhanced production of immunoglobulins
RU2745563C2 (ru) 2016-05-20 2021-03-29 Регенерон Фармасьютикалс, Инк. Способы преодоления иммунологической толерантности с использованием множества направляющих рнк
RU2753585C2 (ru) 2016-06-03 2021-08-18 Регенерон Фармасьютикалз, Инк. Животные, не являющиеся человеком, экспрессирующие экзогенную терминальную дезоксинуклеотидилтрансферазу
ES3046537T3 (en) 2016-11-08 2025-12-02 Regeneron Pharma Steroids and protein-conjugates thereof
AU2017373889B2 (en) 2016-12-07 2025-01-02 Ac Immune Sa Anti-Tau antibodies and methods of use
AU2017373884B2 (en) 2016-12-07 2024-11-14 Ac Immune Sa Anti-tau antibodies and methods of their use
SG11201906540WA (en) * 2017-01-19 2019-08-27 Open Monoclonal Tech Inc Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
IL270594B2 (en) 2017-05-18 2024-06-01 Regeneron Pharma Cyclodextrin protein drug conjugates
EP3679070A1 (en) 2017-09-07 2020-07-15 Augusta University Research Institute, Inc. Antibodies to programmed cell death protein 1
SG11202004151YA (en) 2017-11-07 2020-06-29 Regeneron Pharma Hydrophilic linkers for antibody drug conjugates
IL319417A (en) 2018-01-08 2025-05-01 Regeneron Pharma Steroids and their anti-inflammatory properties
TW202506730A (zh) 2018-03-24 2025-02-16 美商再生元醫藥公司 用於產生抗肽-mhc複合物之治療性抗體的經基因修飾的非人類動物、其製法與用途
CN116420679B (zh) 2018-03-26 2025-10-03 瑞泽恩制药公司 用于测试治疗剂的人源化啮齿动物
CN112533951A (zh) 2018-05-09 2021-03-19 里珍纳龙药品有限公司 抗msr1抗体及其使用方法
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
JP2020146300A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146315A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146317A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146310A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146299A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146306A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146316A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146307A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146312A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146302A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146313A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146318A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146298A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146314A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146303A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146297A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146309A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146304A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146305A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146308A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146301A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
US11701427B2 (en) 2020-04-16 2023-07-18 Regeneron Pharmaceuticals, Inc. Diels-alder conjugation methods
AU2021308190A1 (en) 2020-07-13 2023-02-02 Regeneron Pharmaceuticals, Inc. Camptothecin analogs conjugated to a glutamine residue in a protein, and their use
AU2021342159A1 (en) 2020-09-11 2023-03-02 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
IL301074A (en) 2020-09-14 2023-05-01 Regeneron Pharma Antibody-drug conjugates comprising GLP1 peptidomimetics and their uses
AU2021400584A1 (en) 2020-12-16 2023-06-29 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
EP4051700B1 (en) 2020-12-23 2025-05-07 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
AU2023207960A1 (en) 2022-01-12 2024-07-11 Regeneron Pharmaceuticals, Inc. Camptothecin analogs conjugated to a glutamine residue in a protein, and their use
CN118984837A (zh) 2022-01-28 2024-11-19 乔治穆内公司 作为pd-1激动剂的程序性细胞死亡蛋白1的抗体
AU2023407365A1 (en) 2022-12-21 2025-07-31 Regeneron Pharmaceuticals, Inc. Prodrugs of topoisomerase i inhibitor for adc conjugations and methods of use thereof
WO2025096921A1 (en) 2023-11-03 2025-05-08 Regeneron Pharmaceuticals, Inc. Peptide acids as a glp1r agonist and antibody-drug conjugates thereof

Family Cites Families (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4977081A (en) 1987-05-04 1990-12-11 Adi Diagnostics, Inc. Stable rabbit-mouse hybridomas and secretion products thereof
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5075181A (en) 1989-05-05 1991-12-24 Kennametal Inc. High hardness/high compressive stress multilayer coated tool
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5411881A (en) 1990-07-10 1995-05-02 Nkk Corporation Chicken-specific immunoglobulin G-producing hybridoma
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
JP2835787B2 (ja) 1991-03-22 1998-12-14 キヤノン株式会社 強誘電性液晶素子
CA2078539C (en) * 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5150584A (en) 1991-09-26 1992-09-29 General Motors Corporation Method and apparatus for detecting low refrigerant charge
ATE381614T1 (de) 1992-07-24 2008-01-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
EP0583980A1 (en) 1992-08-20 1994-02-23 Eli Lilly And Company Method for generating monoclonal antibodies from rabbits
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
EP1589107B1 (en) 1992-08-21 2009-12-23 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
FI952658A0 (fi) 1992-12-01 1995-05-31 Protein Design Labs Inc L-selektiinin kanssa reaktiivisia humanisoituja vasta-aineita
DE4309308C1 (de) 1993-03-23 1994-04-14 Siemens Nixdorf Inf Syst Belüftungssystem für Schränke mit stark wärmeerzeugenden elektronischen Funktionseinheiten
IL109168A0 (en) * 1993-04-01 1994-06-24 Univ Columbia A retroviral vector capable of transducing the aldehyde dehydrogenase-1 gene and making cells resistant to the chemotherapeutic agent cyclophosphamide and its derivatives and analogs
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5523226A (en) 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
AU7326796A (en) 1995-10-30 1997-05-22 Spectral Diagnostics Inc. Stable chicken b-cell line and method of use thereof
AU3507297A (en) 1996-06-26 1998-01-14 Baylor College Of Medicine Chromosomal rearrangement by insertion of two recombination substrates
JP4215172B2 (ja) 1996-12-03 2009-01-28 アムジェン フレモント インク． 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
CN1203922A (zh) 1997-03-21 1999-01-06 三共株式会社 人源化抗人fas抗体
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
AU5043200A (en) 1999-05-27 2000-12-18 Human Genome Sciences, Inc. Adam polynucleotides and polypeptides
GB0001448D0 (en) 2000-01-21 2000-03-08 Novartis Ag Organic compounds
NZ524523A (en) * 2000-08-03 2006-02-24 Therapeutic Human Polyclonals Production of humanized antibodies in transgenic animals
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
US7034134B2 (en) 2001-04-26 2006-04-25 Bristol-Myers Squibb Company Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29
CA2446968C (en) 2001-05-11 2012-07-03 Kirin Beer Kabushiki Kaisha Human artificial chromosome containing human antibody .lambda. light chain gene and non-human animal containing the human artificial chromosome capable of genetic transmission
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
WO2003002609A2 (en) 2001-06-28 2003-01-09 Domantis Limited Dual-specific ligand and its use
FR2827302B1 (fr) * 2001-07-13 2003-10-10 Genoway Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations
WO2003031656A1 (en) 2001-10-05 2003-04-17 United States Environmental Protection Agency Genetic testing for male factor infertility
US20060199204A1 (en) 2001-10-05 2006-09-07 U.S. Epa Genetic testing for male factor infertility
AU2002348263B2 (en) 2001-11-30 2008-10-16 Amgen Fremont Inc. Transgenic animals bearing human IgLamda light chain genes
EP1461423B1 (en) 2001-12-03 2008-05-14 Amgen Fremont Inc. Antibody categorization based on binding characteristics
US20030182675A1 (en) 2002-03-22 2003-09-25 Origen Therapeutics Functional disruption of avian immunoglobulin genes
US20050246782A1 (en) 2002-03-22 2005-11-03 Origen Therapeutics Transgenic aves producing human polyclonal antibodies
ES2263984T3 (es) 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
FI117110B (fi) 2002-07-05 2006-06-15 Outokumpu Oy Anodin syöttö sulatusreaktoriin
CN100480260C (zh) 2002-07-18 2009-04-22 克鲁塞尔荷兰公司 抗体混合物的重组生产
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
GB0228210D0 (en) * 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
GB0230201D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Retargeting
JP2006523090A (ja) 2002-12-27 2006-10-12 ドマンティス リミテッド リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体
GB0230203D0 (en) * 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
GB2398784B (en) 2003-02-26 2005-07-27 Babraham Inst Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal
US20100069614A1 (en) * 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
CA2527694C (en) * 2003-05-30 2015-07-14 Hendricus Renerus Jacobus Mattheus Hoogenboom Fab library for the preparation of anti vegf and anti rabies virus fabs
US7205148B2 (en) 2003-06-11 2007-04-17 Regeneron Pharmaceuticals, Inc. Genome mutation by intron insertion into an embryonic stem cell genome
AU2004257292A1 (en) 2003-07-15 2005-01-27 Therapeutic Human Polyclonals, Inc. Humanized immunoglobulin loci
US20050153392A1 (en) 2003-08-11 2005-07-14 Roland Buelow Transgenesis with humanized immunoglobulin loci
RU2251699C1 (ru) 2003-09-25 2005-05-10 Киселев Всеволод Иванович Способ ранней и доклинической диагностики цервикального рака
WO2005038001A2 (en) 2003-10-14 2005-04-28 Therapeutic Human Polyclonals, Inc. Improved transgenesis by sperm-mediated gene transfer
FR2861255B1 (fr) 2003-10-24 2006-02-17 Centre Nat Rech Scient Mammifere non-humain transgenique pour la region constante de la chaine lourde des immunoglobulines humaines de classe a et ses applications.
AU2005215073B2 (en) 2004-02-20 2011-02-03 Woodwelding Ag Implant that can be implanted in osseous tissue, method for producing said implant and corresponding implant
PL2311874T3 (pl) * 2004-07-22 2017-10-31 Univ Erasmus Med Ct Rotterdam Cząsteczki wiążące
PL2767161T3 (pl) 2004-10-19 2018-09-28 Regeneron Pharmaceuticals, Inc. Sposób wytwarzania zwierzęcia homozygotycznego pod względem modyfikacji genetycznej
JP2008517600A (ja) 2004-10-22 2008-05-29 セラピューティック ヒューマン ポリクローナルズ， インコーポレイテッド ヒト以外のトランスジェニック動物における内因性免疫グロブリン発現の抑制
GB0618345D0 (en) * 2006-09-18 2006-10-25 Univ Erasmus Binding molecules
US20090307787A1 (en) 2006-01-25 2009-12-10 Franklin Gerardus Grosveld Generation of heavy-chain only antibodies in transgenic animals
CA2638774C (en) 2006-03-31 2015-11-24 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
HRP20120175T1 (hr) 2006-06-02 2012-03-31 Regeneron Pharmaceuticals Antitijela s visokim afinitetom za humani il-6 receptor
JP5087625B2 (ja) 2006-09-01 2012-12-05 セラピューティック・ヒューマン・ポリクローナルズ・インコーポレーテッド 非ヒトトランスジェニック動物におけるヒトまたはヒト化免疫グロブリンの発現強化
US7605237B2 (en) * 2006-10-02 2009-10-20 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
KR102096731B1 (ko) 2007-06-01 2020-04-02 오픈 모노클로날 테크놀로지, 인코포레이티드 내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물
WO2009013620A2 (en) 2007-06-11 2009-01-29 Erasmus University Medical Center Rotterdam Homologous recombination
ITMI20071522A1 (it) 2007-07-27 2009-01-28 Areta Internat S R L Vaccino idiotipico
CA2694488A1 (en) * 2007-07-31 2009-02-05 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
WO2009097006A2 (en) 2007-08-10 2009-08-06 Medarex, Inc. Hco32 and hco27 and related examples
CN101970491A (zh) 2007-08-30 2011-02-09 沃尔特及伊莱萨霍尔医学研究院 树突状细胞标记物及其用途
KR101922788B1 (ko) 2007-09-26 2018-11-27 추가이 세이야쿠 가부시키가이샤 항체 정상영역 개변체
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US8012714B2 (en) 2008-04-14 2011-09-06 Innovative Targeting Solutions, Inc. Sequence diversity generation in immunoglobulins
EP2288623B1 (en) * 2008-05-23 2013-07-10 Ablexis, LLC Method of generating single vl domain antibodies in transgenic animals
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
CA2729095C (en) 2008-06-27 2018-12-04 Merus B.V. Method for producing a transgenic murine mammal
DK2346994T3 (da) 2008-09-30 2022-02-28 Ablexis Llc Knock-in-mus til fremstilling af kimære antistoffer
CN112690250B (zh) 2008-12-18 2024-03-08 伊拉兹马斯大学鹿特丹医学中心 表达人源化抗体的非人转基因动物及其用途
CA2983133A1 (en) 2009-02-04 2010-08-12 Molecular Innovations Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin, and antibodies used therein
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
CA2757426A1 (en) * 2009-04-07 2010-10-14 Roche Glycart Ag Bispecific anti-erbb-2/anti-c-met antibodies
MY164121A (en) 2009-06-26 2017-11-30 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
AU2010269978B2 (en) 2009-07-08 2016-11-03 Kymab Limited Animal models and therapeutic molecules
RU2425880C2 (ru) 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
CN101620635A (zh) * 2009-08-07 2010-01-06 中兴通讯股份有限公司 页面数据获取方法及服务器、页面更新方法及服务器
ES2595376T3 (es) 2009-12-10 2016-12-29 Regeneron Pharmaceuticals, Inc. Ratones que producen anticuerpos de cadena pesada
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
PL2501817T5 (pl) 2010-02-08 2021-08-16 Regeneron Pharmaceuticals, Inc. Mysz o wspólnym łańcuchu lekkim
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
CA2802591A1 (en) * 2010-06-17 2011-12-22 Kymab Limited Animal models and therapeutic molecules
KR101945352B1 (ko) 2010-06-22 2019-02-07 리제너론 파아마슈티컬스, 인크. 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스
CN105753979B (zh) * 2010-08-02 2021-05-07 瑞泽恩制药公司 制造包含vl结构域的结合蛋白的小鼠
WO2012063048A1 (en) 2010-11-08 2012-05-18 Kymab Limited Cells & vertebrates for enhanced somatic hypermutation and class switch recombination
SG10201913155QA (en) 2011-02-25 2020-02-27 Regeneron Pharma Adam6 mice
AR085404A1 (es) 2011-02-28 2013-09-25 Hoffmann La Roche Proteinas de union a antigeno
AR085403A1 (es) 2011-02-28 2013-09-25 Hoffmann La Roche Proteinas monovalentes que se unen a antigenos
US20120310284A1 (en) 2011-06-03 2012-12-06 Royal Oak Industries Polyaxial pedicle screw
SMT202100357T1 (it) 2011-08-05 2021-07-12 Regeneron Pharma Topi di catena leggera universale umanizzata
DK3311661T3 (da) 2011-09-19 2022-07-11 Kymab Ltd Manipulation af immunoglobulin-gendiversitet og terapeutiske lægemidler med flere antistoffer
EP3741862A1 (en) 2011-09-19 2020-11-25 Kymab Limited Animals, repertoires & methods for the production of human antibodies
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
KR20140082824A (ko) 2011-10-17 2014-07-02 리제너론 파아마슈티컬스, 인크. 제한된 면역글로불린 중쇄 마우스
GB2496375A (en) 2011-10-28 2013-05-15 Kymab Ltd A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
HUE044266T2 (hu) 2011-12-20 2019-10-28 Regeneron Pharma Humanizált könnyûláncú egerek
SI2809150T1 (sl) 2012-02-01 2019-11-29 Regeneron Pharma Humanizirane miši, ki izražajo težke verige z domenami VL
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
HRP20181648T1 (hr) 2013-04-16 2019-01-25 Regeneron Pharmaceuticals, Inc. Ciljana modifikacija genoma štakora
SG11201607015VA (en) 2014-03-21 2016-09-29 Regeneron Pharma V<sb>L</sb> ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICS
CA3124228C (en) 2014-03-21 2024-05-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
JP2018508224A (ja) 2015-03-19 2018-03-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗原を結合する軽鎖可変領域を選択する非ヒト動物

Also Published As

Publication number Publication date
SMT201700023B (it) 2017-03-08
RU2017106292A3 (es) 2020-12-10
IL271804A (en) 2020-02-27
JP2016054746A (ja) 2016-04-21
CN113150121A (zh) 2021-07-23
US20210163628A1 (en) 2021-06-03
RU2612903C2 (ru) 2017-03-13
US10954310B2 (en) 2021-03-23
KR102306967B1 (ko) 2021-10-01
EP2947151A1 (en) 2015-11-25
EP3960865A1 (en) 2022-03-02
HRP20170322T1 (hr) 2017-04-21
KR20200116547A (ko) 2020-10-12
IL271804B1 (en) 2024-11-01
BR112013002695A2 (pt) 2017-03-01
NZ606824A (en) 2015-05-29
PT2601298T (pt) 2017-01-09
US20170226231A1 (en) 2017-08-10
PL2601298T3 (pl) 2017-03-31
KR102434557B1 (ko) 2022-08-23
MX2023001793A (es) 2023-03-10
US9686970B2 (en) 2017-06-27
JP6146913B2 (ja) 2017-06-14
MX2013001360A (es) 2013-06-28
CY1118562T1 (el) 2017-07-12
MY172618A (en) 2019-12-06
CN113150121B (zh) 2024-08-16
US12486335B2 (en) 2025-12-02
JP2013535213A (ja) 2013-09-12
US20140130193A1 (en) 2014-05-08
IL315833A (en) 2024-11-01
IL224523B (en) 2018-04-30
CN103154255B (zh) 2016-04-06
MX345251B (es) 2017-01-23
HK1217511A1 (en) 2017-01-13
KR102163138B1 (ko) 2020-10-08
CA3250882A1 (en) 2025-11-29
JP7110257B2 (ja) 2022-08-01
DK2601298T3 (en) 2017-02-27
KR20130100277A (ko) 2013-09-10
US9516868B2 (en) 2016-12-13
EP2601298A1 (en) 2013-06-12
HK1181810A1 (en) 2013-11-15
HUE031903T2 (en) 2017-08-28
MX363084B (es) 2019-03-07
ES2612459T3 (es) 2017-05-17
US20140130194A1 (en) 2014-05-08
CA2807282A1 (en) 2012-02-09
RU2017106292A (ru) 2019-01-21
US20170223939A1 (en) 2017-08-10
CN113150121B9 (zh) 2024-11-26
CN105753979A (zh) 2016-07-13
JP2018046872A (ja) 2018-03-29
US20220177606A1 (en) 2022-06-09
CN103154255A (zh) 2013-06-12
CN118791596A (zh) 2024-10-18
MX350591B (es) 2017-09-11
AU2011285919A1 (en) 2013-02-28
IL271804B2 (en) 2025-03-01
KR20190095511A (ko) 2019-08-14
KR102008655B1 (ko) 2019-08-08
RU2013109068A (ru) 2014-09-10
IL258338A (en) 2018-05-31
JP6759303B2 (ja) 2020-09-23
RU2750219C2 (ru) 2021-06-24
SG10201912639SA (en) 2020-02-27
IL258338B (en) 2020-01-30
AU2011285919B2 (en) 2015-04-30
JP2020078328A (ja) 2020-05-28
SMT201700023T1 (it) 2017-03-08
EP2601298B1 (en) 2016-11-30
JP2021119792A (ja) 2021-08-19
NZ707327A (en) 2017-01-27
BR112013002695B1 (pt) 2023-01-24
RS55495B1 (sr) 2017-04-28
JP2019047805A (ja) 2019-03-28
KR20210118972A (ko) 2021-10-01
SI2601298T1 (sl) 2017-03-31
JP7078400B2 (ja) 2022-05-31
NZ724003A (en) 2021-03-26
US20120096572A1 (en) 2012-04-19
SG10201504971QA (en) 2015-07-30
CN105753979B (zh) 2021-05-07
LT2601298T (lt) 2017-03-10
SG187673A1 (en) 2013-03-28
AU2011285919C1 (en) 2015-09-17
WO2012018764A1 (en) 2012-02-09
NZ740900A (en) 2023-11-24

Similar Documents

Publication Publication Date Title
MX2023001793A (es) Ratones que producen proteinas de union que comprenden dominios vl.
WO2015143414A3 (en) Non-human animals that make single domain binding proteins
MY172718A (en) Humanized universal light chain mice
SG10201900580RA (en) Non-human animals with modified immunoglobulin heavy chain sequences
CY1121864T1 (el) Τρωκτικα που εκφραζουν ευαισθητες στο ρη αλληλουχιες ανοσοσφαιρινης
MX2020010837A (es) Ratones que expresan un repertorio limitado de cadena ligera de inmunoglobulina.
CY1121217T1 (el) Μεθοδοι για συγκομιδη καλλιεργειων κυτταρου θηλαστικων
MY165287A (en) Mice expressing a light chain with human lambda variable and mouse constant regions
EP2734622A4 (en) COMPOSITIONS AND METHOD FOR THE PROGRAMMING OF CELLS WITHOUT GENETIC MODIFICATION FOR THE REPAIR OF CARTILAGE DAMAGE
EA201171148A1 (ru) Антитело-антагонист, специфичное для гетеродимера альфа-4-бета-7
MX353278B (es) Raton con cadena ligera comun.
SG10201808083VA (en) Vl antigen binding proteins exhibiting distinct binding characteristics
MX2020012356A (es) Sobreexpresion de reguladores de la ruta de n-glicosilacion para modular la glicosilacion de proteinas recombinantes.
MX358243B (es) Anticuerpos anti-vasa y metodos de produccion y uso de los mismos.
MX2016013955A (es) Drimenol-sintasas y metodo de produccion de drimenol.
GB201116495D0 (en) Human vpreb &amp; chimaeric surrogate light chains in transgenic non-human vertebrates
CY1125118T1 (el) Αντι-ngf αντισωματα και χρηση αυτων
PH12012501656A1 (en) Complexes of an3-interacting proteins and their use for plant growth promotion
HK40061025A (en) Artificial expression constructs for selectively modulating gene expression in interneurons
HK1231692A1 (en) Non-human animals that make single domain binding proteins
NZ810163A (en) Mice that make binding proteins comprising vl domains
HK1192586A (en) Humanized universal light chain mice